{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:50:38Z","timestamp":1780645838115,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"KCE","award":["COV201004"],"award-info":[{"award-number":["COV201004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The COVID-19 pandemic reached Europe in early 2020. Convalescent plasma is used without a consistent evidence of efficacy. Our hypothesis is that passive immunization with plasma collected from patients having contracted COVID-19 and developed specific neutralizing antibodies may alleviate symptoms and reduce mortality in patients treated with mechanical ventilation for severe respiratory failure during the evolution of SARS-CoV-2 pneumonia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We plan to include 500 adult patients, hospitalized in 16 Belgian intensive care units between September 2020 and 2022, diagnosed with SARS-CoV-2 pneumonia, under mechanical ventilation for less than 5\u00a0days and a clinical frailty scale less than 6. The study treatment will be compared to standard of care and allocated by randomization in a 1 to 1 ratio without blinding. The main endpoint will be mortality at day 28. We will perform an intention to treat analysis. The number of patients to include is based on an expected mortality rate at day 28 of 40 percent and an expected relative reduction with study intervention of 30 percent with \u03b1 risk of 5 percent and \u03b2 risk of 20 percent.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study will assess the efficacy of plasma in the population of mechanically ventilated patients. A stratification on the delay from mechanical ventilation and inclusion will allow to approach the optimal time use. Selecting convalescent plasmas with a high titer of neutralizing antibodies against SARS-CoV-2 will allow a homogeneous study treatment. The inclusion in the study is based on the consent of the patient or his\/her legal representative, and the approval of the Investigational Review Board of the University hospital of Li\u00e8ge, Belgium. A data safety monitoring board (DSMB) has been implemented. Interim analyses have been planned at 100, 2002, 300 and 400 inclusions in order to decide whether the trail should be discontinued prematurely for ethical issues. We plan to publish our results in a peer-reviewed journal and to present them at national and international conferences.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Funding and registration<\/jats:title>\n                <jats:p>The trial is funded by the Belgian Health Care Knowledge Center KCE # COV201004<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinicaltrials.gov registration number NCT04558476. Registered 14 September 2020\u2014Retrospectively registered, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04558476\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04558476<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-020-01361-x","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T07:03:12Z","timestamp":1607324592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6466-0065","authenticated-orcid":false,"given":"Beno\u00eet","family":"Misset","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hoste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Fran\u00e7oise","family":"Donneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Meyfroidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Moutschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Compernolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Gothot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Desmecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutien","family":"Garigliany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tome","family":"Najdovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Fran\u00e7ois","family":"Laterre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"key":"1361_CR1","unstructured":"Coronavirus COVID-19 (2019-nCoV) [Internet]. [cited 2020 Apr 12]. https:\/\/gisanddata.maps.arcgis.com\/apps\/opsdashboard\/index.html#\/bda7594740fd40299423467b48e9ecf6"},{"key":"1361_CR2","unstructured":"Epistat \u2013 Covid-19 [Internet]. [cited 2020 Apr 12]. https:\/\/epistat.wiv-isp.be\/covid\/covid-19.html"},{"key":"1361_CR3","unstructured":"ICNARC \u2013 Reports [Internet]. [cited 2020 Apr 12]. https:\/\/www.icnarc.org\/Our-Audit\/Audits\/Cmp\/Reports"},{"key":"1361_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0994","volume-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan","author":"C Wu","year":"2020","unstructured":"Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. JAMA Intern Med: China; 2020."},{"key":"1361_CR5","first-page":"576","volume":"580","author":"E Callaway","year":"2020","unstructured":"Callaway E. The race for coronavirus vaccines: a graphical guide. Nat Publishing Group. 2020;580:576\u20137.","journal-title":"Nat Publishing Group"},{"key":"1361_CR6","doi-asserted-by":"crossref","unstructured":"Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020","DOI":"10.1001\/jama.2020.4783"},{"key":"1361_CR7","unstructured":"Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;"},{"key":"1361_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jama.2020.10044","volume":"324","author":"L Li","year":"2020","unstructured":"Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324:460\u201370.","journal-title":"JAMA"},{"key":"1361_CR9","doi-asserted-by":"crossref","unstructured":"Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest. 2020","DOI":"10.1016\/j.mayocp.2021.06.010"},{"key":"1361_CR10","doi-asserted-by":"crossref","unstructured":"Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv. Cold Spring Harbor Laboratory Press; 2020;2020.08.12.20169359.","DOI":"10.1101\/2020.08.12.20169359"},{"key":"1361_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.4616","volume-title":"Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai","author":"F Wu","year":"2020","unstructured":"Wu F, Liu M, Wang A, Lu L, Wang Q, Gu C, et al. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai. JAMA Intern Med: China; 2020."},{"key":"1361_CR12","first-page":"304","volume":"10","author":"H-S Wu","year":"2004","unstructured":"Wu H-S, Chiu S-C, Tseng T-C, Lin S-F, Lin J-H, Hsu Y-H, et al. Serologic and molecular biologic methods for SARS-associated coronavirus infection. Taiwan Emerg Inf Dis. 2004;10:304\u201310.","journal-title":"Taiwan Emerg Inf Dis"},{"key":"1361_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00134-019-05853-1","volume":"46","author":"B Guidet","year":"2020","unstructured":"Guidet B, de Lange DW, Boumendil A, Leaver S, Watson X, Boulanger C, et al. The contribution of frailty, cognition, activity of daily life and comorbidities on outcome in acutely admitted patients over 80 years in European ICUs: the VIP2 study. Intensive Care Med. 2020;46:57\u201369.","journal-title":"Intensive Care Med"},{"key":"1361_CR14","unstructured":"RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. New Engl J Med. 2020"},{"key":"1361_CR15","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"WS Lee","year":"2020","unstructured":"Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol . 2020;5:1185\u201391.","journal-title":"Nat Microbiol"}],"updated-by":[{"DOI":"10.1186\/s12890-021-01574-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000}}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01361-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-020-01361-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01361-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T06:03:50Z","timestamp":1627365830000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-020-01361-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1361"],"URL":"https:\/\/doi.org\/10.1186\/s12890-020-01361-x","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12890-021-01574-8","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"17 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following publication, the authors have flagged inappropriate sentences for removal; please see the linked correction article for further details.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12890-021-01574-8","URL":"https:\/\/doi.org\/10.1186\/s12890-021-01574-8","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The inclusion in the study is based on the written consent of the patient or his\/her legal representative, according to the Helsinki declaration and the Belgian law. The eligible patients will be unable to speak\u2014due to tracheal intubation\u2014and most often likely not able to understand the information about the benefits and risks of the trial\u2014due to sedation and\/or confusion due to COVID-induced sepsis. Their relatives will likely be only contacted by phone and asked to send a written consent by email, according to the guidelines of the participating ICU, which most frequently preclude access of visitors to the hospitals due to the pandemic aspect of COVID-19. This protocol has been approved by the Investigational Review Board \/ Central Ethics Committee of the University hospital of Li\u00e8ge, Belgium on September 1, 2020, number # 2020\/239.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}